Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical BCG in Invasive Bladder Cancer
NCT02365207Terminated
- Sponsor
- UT Health San Antonio
- Start
- Nov 2013
- Primary completion
- Sep 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bcg vaccine in bladder cancer, sponsored by UT Health San Antonio. Primary endpoint: Ability of BCG to Enhance Tumor Specific Immunity. Started Nov 2013; status: terminated.
02
Drugs
bcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02365207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365207.